Download PDF
Horm Metab Res 2023; 55(02): 114-123
DOI: 10.1055/a-1956-2961
Original Article: Endocrine Care

Circulating Growth Differentiation Factor 15 and Preeclampsia: A Meta-Analysis

Lihong Wang
1   Department of Obstetrics and Gynecology, Baogang Hospital, Baotou, China
,
Qiuli Yang
1   Department of Obstetrics and Gynecology, Baogang Hospital, Baotou, China
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Growth differentiation factor 15 (GDF-15) has been suggested as a potential biomarker of preeclampsia. However, previous studies evaluating circulating GDF-15 in women with preeclampsia showed inconsistent results. A meta-analysis was performed accordingly in this study. Observational studies comparing circulating GDF-15 between women with preeclampsia normal pregnancy were identified by search of electronic databases including PubMed, Embase, Web of Science, Wanfang, and CNKI. The Newcastle-Ottawa Scale (NOS) was used for assessing the quality of the studies. A randomized-effect model incorporating the possible between-study heterogeneity was used to pool the results. Eleven observational studies including 498 women with preeclampsia and 2349 women with normal pregnancy contributed to the meta-analysis. Results showed that compared to controls of women with normal pregnancy at least matched for gestational ages, women with preeclampsia had significantly higher circulating GDF-15 at the diagnosis [standard mean difference (SMD): 0.66, 95% confidence interval (CI): 0.16 to 1.17, p=0.01, I2=93%]. Subgroup analysis showed consistent results in women with preterm and term preeclampsia in Asian and non-Asian women and in studies with different quality scores, which were not statistically significant between subgroups (p for subgroup difference>0.05). Moreover, a higher level of GDF-15 was also found before the diagnosis in women who subsequently developed preeclampsia than those who did not (SMD: 1.32, 95% CI: 0.45 to 2.18, p=0.003, I2=89%). In conclusion, a higher circulating GDF-15 is observed in women with preeclampsia even before the diagnosis of the disease.

Key words

growth differentiation factor 15 - preeclampsia - biomarker - pregnancy - meta-analysis


Publication History

Received: 30 August 2022

Accepted after revision: 21 September 2022

Article published online:
21 November 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Erez O, Romero R, Jung E. et al. Preeclampsia and eclampsia: the conceptual evolution of a syndrome. Am J Obstet Gynecol 2022; 226: S786-S803
    CrossrefPubMedGoogle Scholar
  • 2 Rana S, Lemoine E, Granger JP. et al. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res 2019; 124: 1094-1112
    CrossrefPubMedGoogle Scholar
  • 3 Miller EC, Wilczek A, Bello NA. et al. Pregnancy, preeclampsia and maternal aging: from epidemiology to functional genomics. Ageing Res Rev 2022; 73: 101535
    CrossrefPubMedGoogle Scholar
  • 4 Fishel Bartal M, Sibai BM. Eclampsia in the 21st century. Am J Obstet Gynecol 2022; 226: S1237-S1253
    CrossrefPubMedGoogle Scholar
  • 5 Executive summary: Workshop on preeclampsia, January 25-26, 2021, cosponsored by the Society for Maternal-Fetal Medicine and the Preeclampsia Foundation Am J Obstet Gynecol 2021; 225: B2-B7
    PubMed
  • 6 Backes CH, Markham K, Moorehead P. et al. Maternal preeclampsia and neonatal outcomes. J Pregnancy 2011; 214365
    PubMedGoogle Scholar
  • 7 Ukah UV, De Silva DA, Payne B. et al. Prediction of adverse maternal outcomes from pre-eclampsia and other hypertensive disorders of pregnancy: A systematic review. Pregnancy Hypertens 2018; 11: 115-123
    CrossrefPubMedGoogle Scholar
  • 8 Wu P, Haththotuwa R, Kwok CS. et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2017; 10: e003497
    CrossrefPubMedGoogle Scholar
  • 9 Yao M, Xiao Y, Yang Z. et al. Identification of biomarkers for preeclampsia based on metabolomics. Clin Epidemiol 2022; 14: 337-360
    CrossrefPubMedGoogle Scholar
  • 10 Jung E, Romero R, Yeo L. et al. The etiology of preeclampsia. Am J Obstet Gynecol 2022; 226: S844-S866
    CrossrefPubMedGoogle Scholar
  • 11 MacDonald TM, Walker SP, Hannan NJ. et al. Clinical tools and biomarkers to predict preeclampsia. EBioMedicine 2022; 75: 103780
    CrossrefPubMedGoogle Scholar
  • 12 Nirupama R, Divyashree S, Janhavi P. et al. Preeclampsia: pathophysiology and management. J Gynecol Obstet Hum Reprod 2021; 50: 101975
    CrossrefPubMedGoogle Scholar
  • 13 Qu H, Khalil RA. Vascular mechanisms and molecular targets in hypertensive pregnancy and preeclampsia. Am J Physiol Heart Circ Physiol 2020; 319: H661-H681
    CrossrefPubMedGoogle Scholar
  • 14 Desmedt S, Desmedt V, De Vos L. et al. Growth differentiation factor 15: A novel biomarker with high clinical potential. Crit Rev Clin Lab Sci 2019; 56: 333-350
    CrossrefPubMedGoogle Scholar
  • 15 Wischhusen J, Melero I, Fridman WH. Growth/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint. Front Immunol 2020; 11: 951
    CrossrefPubMedGoogle Scholar
  • 16 Eddy AC, Trask AJ. Growth differentiation factor-15 and its role in diabetes and cardiovascular disease. Cytokine Growth Factor Rev 2021; 57: 11-18
    CrossrefPubMedGoogle Scholar
  • 17 Wollert KC, Kempf T, Wallentin L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin Chem 2017; 63: 140-151
    CrossrefPubMedGoogle Scholar
  • 18 Wang D, Day EA, Townsend LK. et al. GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease. Nat Rev Endocrinol 2021; 17: 592-607
    CrossrefPubMedGoogle Scholar
  • 19 Lockhart SM, Saudek V, O’Rahilly S. GDF15: A hormone conveying somatic distress to the brain. Endocr Rev 2020; 41: bnaa007
    CrossrefPubMedGoogle Scholar
  • 20 Andersson-Hall U, Svedin P, Mallard C. et al. Growth differentiation factor 15 increases in both cerebrospinal fluid and serum during pregnancy. PLoS One 2021; 16: e0248980
    CrossrefPubMedGoogle Scholar
  • 21 Tong S, Marjono B, Brown DA. et al. Serum concentrations of macrophage inhibitory cytokine 1 (MIC 1) as a predictor of miscarriage. Lancet 2004; 363: 129-130
    CrossrefPubMedGoogle Scholar
  • 22 Tong S, Ngian GL, Onwude JL. et al. Diagnostic accuracy of maternal serum macrophage inhibitory cytokine-1 and pregnancy-associated plasma protein-A at 6-10 weeks of gestation to predict miscarriage. Obstet Gynecol 2012; 119: 1000-1008
    CrossrefPubMedGoogle Scholar
  • 23 Yakut K, Ocal DF, Ozturk FH. et al. Is GDF-15 level associated with gestational diabetes mellitus and adverse perinatal outcomes?. Taiwan J Obstet Gynecol 2021; 60: 221-224
    CrossrefPubMedGoogle Scholar
  • 24 Marjono AB, Brown DA, Horton KE. et al. Macrophage inhibitory cytokine-1 in gestational tissues and maternal serum in normal and pre-eclamptic pregnancy. Placenta 2003; 24: 100-106
    CrossrefPubMedGoogle Scholar
  • 25 Sugulle M, Dechend R, Herse F. et al. Circulating and placental growth-differentiation factor 15 in preeclampsia and in pregnancy complicated by diabetes mellitus. Hypertension 2009; 54: 106-112
    CrossrefPubMedGoogle Scholar
  • 26 Chen Q, Wang Y, Zhao M. et al. Serum levels of GDF15 are reduced in preeclampsia and the reduction is more profound in late-onset than early-onset cases. Cytokine 2016; 83: 226-230
    CrossrefPubMedGoogle Scholar
  • 27 Shi J, Chen ZQ. Determination and clinical significance of plasma growth differentiation factor 15 in hypertensive disorders complicating pregnancy. Chin J Family Plan Gynecol 2017; 9: 48-51
    PubMedGoogle Scholar
  • 28 Temel Yuksel I, Mathyk BA, Aslan Cetin B. et al. Maternal levels of growth differentiation factor-15 in patients with preeclampsia. Hypertens Pregnancy 2018; 37: 192-196
    CrossrefPubMedGoogle Scholar
  • 29 Ma ZQ, Han Q. Combined diagnostic efficacy of GSTM1, PIGF, and GDF-15 for hypertensive disorders in pregnancy. Int J Lab Med 2019; 40: 2063-2165
    PubMedGoogle Scholar
  • 30 Cruickshank T, MacDonald TM, Walker SP. et al. Circulating growth differentiation factor 15 is increased preceding preeclampsia diagnosis: implications as a disease biomarker. J Am Heart Assoc 2020; 10: e020302
    CrossrefPubMedGoogle Scholar
  • 31 Wertaschnigg D, Rolnik DL, Nie G. et al. Second- and third-trimester serum levels of growth-differentiation factor-15 in prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2020; 56: 879-884
    CrossrefPubMedGoogle Scholar
  • 32 Tahaa A, Abd Raboub I, Abd Halim H. The value of maternal serum levels of growth differentiation factor-15 as a predictor of preeclampsia. Sci J Al-Azhar Med Faculty Girls 2021; 5: 204-210
    PubMedGoogle Scholar
  • 33 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71
    Google Scholar
  • 34 Page MJ, Moher D, Bossuyt PM. et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021; 372: n160
    CrossrefPubMedGoogle Scholar
  • 35 Higgins J, Thomas J, Chandler J. et al. Cochrane handbook for systematic reviews of interventions version 6.2. The Cochrane Collaboration. 2021 www.training.cochrane.org/handbook
    PubMedGoogle Scholar
  • 36 ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002 Obstet Gynecol 2002; 99: 159-167
    PubMed
  • 37 Wells GA, Shea B, O’Connell D. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2010 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
    PubMed
  • 38 Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. 2011 www.cochranehandbook.org
    PubMedGoogle Scholar
  • 39 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558
    CrossrefPubMedGoogle Scholar
  • 40 Egger M, Davey Smith G, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
    CrossrefPubMedGoogle Scholar
  • 41 Moore AG, Brown DA, Fairlie WD. et al. The transforming growth factor-ss superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. J Clin Endocrinol Metab 2000; 85: 4781-4788
    PubMedGoogle Scholar
  • 42 Li H, Dakour J, Guilbert LJ. et al. PL74, a novel member of the transforming growth factor-beta superfamily, is overexpressed in preeclampsia and causes apoptosis in trophoblast cells. J Clin Endocrinol Metab 2005; 90: 3045-3053
    CrossrefPubMedGoogle Scholar
  • 43 Kiyokoba R, Uchiumi T, Yagi M. et al. Mitochondrial dysfunction-induced high hCG associated with development of fetal growth restriction and pre-eclampsia with fetal growth restriction. Sci Rep 2022; 12: 4056
    CrossrefPubMedGoogle Scholar
  • 44 Zuo Q, Zou Y, Huang S. et al. Aspirin reduces sFlt-1-mediated apoptosis of trophoblast cells in preeclampsia. Mol Hum Reprod 2021; 27: gaaa089
    CrossrefPubMedGoogle Scholar
  • 45 Arkoumani M, Papadopoulou-Marketou N. et al. The clinical impact of growth differentiation factor-15 in heart disease: A 2019 update. Crit Rev Clin Lab Sci 2020; 57: 114-125
    CrossrefPubMedGoogle Scholar
  • 46 Tenorio MB, Ferreira RC, Moura FA. et al. Cross-talk between oxidative stress and inflammation in preeclampsia. Oxid Med Cell Longev 2019; 2019: 8238727
    CrossrefPubMedGoogle Scholar
  • 47 Smith TA, Kirkpatrick DR, Kovilam O. et al. Immunomodulatory role of vitamin D in the pathogenesis of preeclampsia. Expert Rev Clin Immunol 2015; 11: 1055-1063
    CrossrefPubMedGoogle Scholar
  • 48 Li E, Chen P, Lu J. et al. Serum growth differentiation factor 15 is closely associated with metabolic abnormalities in Chinese pregnant women. J Diabetes Investig 2021; 12: 1501-1507
    CrossrefPubMedGoogle Scholar
  • 49 Tang M, Luo M, Lu W. et al. Serum growth differentiation factor 15 is associated with glucose metabolism in the third trimester in Chinese pregnant women. Diabetes Res Clin Pract 2019; 156: 107823
    CrossrefPubMedGoogle Scholar